A team of New York University-led researchers has developed a screen for mosaic mutations.

In Nature this week: cryo-electron microscopy is the Method of the Year, and more.

New bioinformatics businesses bloomed over the past year in spite of a challenging market and encroachment from instrument vendors and other larger entities.

The quiet of holiday breaks lends itself to getting research done, Stat News writes.

University of Washington and Fred Hutchinson Cancer Research Center researchers examine factors influencing clinical cancer trials with low participant accrual rates.

With their new collaboration, the parties look to put into more direct contact the research and implementation portions of the personalized medicine pipeline.

The year in personalized medicine started at the White House and ended with a congressional hearing, capturing the enthusiasm and barriers in the field.

The cancer genetics testing provider acquired its new business unit from GE Healthcare.

Researchers saw higher-than-anticipated genetic diversity when they sequenced a handful of Plasmodium vivax isolates from a malaria endemic region in Colombia.

Researchers get a clear image of the DROSHA protein and gain a better understanding of the Microprocessor complex involved in miRNA biogenesis. 

UK researchers have technically validated a qPCR testing method for a panel of four microRNAs with high sensitivity in diagnosing and monitoring rare tumors.

The US Department of Justice sued the company for paying doctors to perform its genomic tests, and then obtaining government reimbursements.

A patent examiner has issued an Initial Interference Memo in the CRISPR patent fight, possibly leading to an interference proceeding, according to the Law and Biosciences Blog.

After falling for three years in a row, mergers and acquisitions in the omics space rose sharply in 2015, driven by a few billion-dollar-plus deals.

With ProteinPaint, investigators can visualize sequence mutations, gene fusions, and RNA expression to interpret patterns in germline and tumor samples.

The work offers a proof of concept for the notion that dynamic models of signaling could serve as more effective biomarkers than discrete molecular markers.

In Genome Biology this week: genetic and environmental influence on human methylome variation, brackish water microbiome, and more.

After an autumn dip, biotech stocks are on the rise, though investors tell the Wall Street Journal that the sector may remain volatile in the New Year.

Two editors at The Verge discuss investment into 'disruptive' healthcare companies.

Nearly a dozen researchers, including the European Bioinformatics Institute's Ewan Birney, share the state of their field at PLOS Medicine.

A study in the New England Journal of Medicine showing that NIPT outperformed standard screening for T21 topped the list of most-read stories in 2015.

The Salt Lake City-based company said it would use the $18.4 million in expected gross aggregate proceeds for product pipeline development and customer growth.

Stat News speaks with William Marshall, the president of miRagen Therapeutics and co-owner of Twisted Pine Brewing.

The genetic evidence supports a link between migrations and important cultural shifts like the emergence of agriculture or metal tools occurring in parallel.

The company's stock faces a potential delisting from Nasdaq for failing to meet the stock exchange's $1 minimum bid price for 30 consecutive days.